N-(氨基硫代甲酰)丙酰胺 | 6965-57-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫脲类
• 中文名称: N-(氨基硫代甲酰)丙酰胺
• 英文名称: propionyl-thiourea
• 英文别名: Propionyl-thioharnstoff；N-(aminothioxomethyl)propionamide；N-carbamothioylpropanamide
• CAS: 6965-57-7
• 化学式: C₄H₈N₂OS
• mdl: MFCD01675767
• 分子量: 132.186
• InChiKey: VVWCJSVUWOIXAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  87.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  methyl (1R,2S)-1-[[(2S,4R)-4-[2-(2-bromoacetyl)-7-methoxy-8-methylquinolin-4-yl]oxy-1-[(2S)-2-(cyclopentyloxycarbonylamino)-3,3-dimethylbutanoyl]pyrrolidine-2-carbonyl]amino]-2-ethenylcyclopropane-1-carboxylate 、 N-(氨基硫代甲酰)丙酰胺 以 异丙醇 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335)

  摘要：

  C-Terminal carboxylic acid containing inhibitors of the NS3 protease are reported. A novel series of linear tripeptide inhibitors that are very potent and selective against the NS3 protease are described. A substantial contribution to the potency of these linear inhibitors arises from the introduction of a C8 substituent on the B-ring of the quinoline moiety found on the P2 of these inhibitors. The introduction of a CS methyl group results not only in a modest increase in the cell-based potency of these inhibitors but more importantly in a much better pharmacokinetic profile in rats as well. Exploration of C8-substitutions led to the identification of the bromo derivative as the best group at this position, resulting in a significant increase in the cell-based potency of this class of inhibitors. Structure activity studies on the C8-bromo derivatives ultimately led to the discovery of clinical candidate 29 (BI 201335), a very potent and selective inhibitor of genotypel NS3 protease with a promising PK profile in rats.

  DOI：

  10.1021/jm100690x
• 作为产物：
  描述：

  丙酰氯 、 硫脲 在 甲苯 作用下， 生成 N-(氨基硫代甲酰)丙酰胺
  参考文献：
  名称：

  Moore; Crossley, Journal of the American Chemical Society, 1940, vol. 62, p. 3274

  摘要：

  DOI：

文献信息

• Stereoselective or Exclusive Synthesis of Ethyl (Z)-2-(2-Substituted-thiazol-4-yl)pent-2-enoates from Ethyl (E/Z)-2-(2-Bromoacetyl)pent-2-enoate
  作者：Ya-Fei Ji、Jiao-Jiao Zhai、Jian-An Jiang、Shun-Li Zhang、Cheng Chen、Hong-Wei Liu、Dao-Hua Liao

  DOI：10.1055/s-0033-1338954

  日期：——

  cis-configuration formation, and opportunely blocking a potential E/Z isomerization. The practical applicability was highlighted by the synthesis of (Z)-2-(2-tert-butoxycarbonylaminothiazol-4-yl)pent-2-enoic acid, a commercially important side-chain material of cefcapene pivoxil, in a two-step procedure.

  从 (E/Z)-2-(2-溴乙酰基)pent-2 乙基 (E/Z)-2-(2-溴乙酰基)pent-2 制备一系列 (Z)-2-(2-取代-噻唑-4-基)pent-2-enoates 的立体选择性或排他性方法-烯酸酯和硫脲或硫代酰胺的产率很高。这种方法涉及季碳立体控制的顺式构型形成，并适时地阻止潜在的 E/Z 异构化。(Z)-2-(2-tert-butoxycarbonylaminothiazol-4-yl)pent-2-enoic acid，一种商业上重要的cefcapene pivoxil侧链材料，通过两步法合成，突出了实际适用性.
• [EN] HEPATITIS C INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE L'HÉPATITE C
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010034105A8

  公开（公告）日：2011-01-06
• Moore; Crossley, Journal of the American Chemical Society, 1940, vol. 62, p. 3274
  作者：Moore、Crossley

  DOI：——

  日期：——
• Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335)
  作者：Montse Llinàs-Brunet、Murray D. Bailey、Nathalie Goudreau、Punit K. Bhardwaj、Josée Bordeleau、Michael Bös、Yves Bousquet、Michael G. Cordingley、Jiamin Duan、Pat Forgione、Michel Garneau、Elise Ghiro、Vida Gorys、Sylvie Goulet、Ted Halmos、Stephen H. Kawai、Julie Naud、Marc-André Poupart、Peter W. White

  DOI：10.1021/jm100690x

  日期：2010.9.9

  C-Terminal carboxylic acid containing inhibitors of the NS3 protease are reported. A novel series of linear tripeptide inhibitors that are very potent and selective against the NS3 protease are described. A substantial contribution to the potency of these linear inhibitors arises from the introduction of a C8 substituent on the B-ring of the quinoline moiety found on the P2 of these inhibitors. The introduction of a CS methyl group results not only in a modest increase in the cell-based potency of these inhibitors but more importantly in a much better pharmacokinetic profile in rats as well. Exploration of C8-substitutions led to the identification of the bromo derivative as the best group at this position, resulting in a significant increase in the cell-based potency of this class of inhibitors. Structure activity studies on the C8-bromo derivatives ultimately led to the discovery of clinical candidate 29 (BI 201335), a very potent and selective inhibitor of genotypel NS3 protease with a promising PK profile in rats.